Neutralization Tests
"Neutralization Tests" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Descriptor ID |
D009500
|
MeSH Number(s) |
E01.370.225.812.735.550 E05.200.812.735.550 E05.478.594.760.550
|
Concept/Terms |
Neutralization Tests- Neutralization Tests
- Neutralization Test
- Test, Neutralization
- Tests, Neutralization
|
Below are MeSH descriptors whose meaning is more general than "Neutralization Tests".
Below are MeSH descriptors whose meaning is more specific than "Neutralization Tests".
This graph shows the total number of publications written about "Neutralization Tests" by people in this website by year, and whether "Neutralization Tests" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1982 | 0 | 1 | 1 | 1985 | 0 | 2 | 2 | 1986 | 0 | 1 | 1 | 1987 | 0 | 1 | 1 | 1988 | 0 | 3 | 3 | 1989 | 0 | 2 | 2 | 1991 | 0 | 3 | 3 | 1992 | 1 | 2 | 3 | 1993 | 0 | 3 | 3 | 1994 | 0 | 1 | 1 | 1995 | 0 | 2 | 2 | 1996 | 0 | 3 | 3 | 1999 | 0 | 2 | 2 | 2000 | 0 | 1 | 1 | 2001 | 0 | 1 | 1 | 2003 | 0 | 2 | 2 | 2006 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2008 | 0 | 1 | 1 | 2009 | 0 | 2 | 2 | 2010 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2013 | 1 | 1 | 2 | 2014 | 0 | 1 | 1 | 2017 | 0 | 1 | 1 | 2021 | 0 | 6 | 6 | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neutralization Tests" by people in Profiles.
-
Tang J, Novak T, Hecker J, Grubbs G, Zahra FT, Bellusci L, Pourhashemi S, Chou J, Moffitt K, Halasa NB, Schwartz SP, Walker TC, Tarquinio KM, Zinter MS, Staat MA, Gertz SJ, Cvijanovich NZ, Schuster JE, Loftis LL, Coates BM, Mack EH, Irby K, Fitzgerald JC, Rowan CM, Kong M, Flori HR, Maddux AB, Shein SL, Crandall H, Hume JR, Hobbs CV, Tremoulet AH, Shimizu C, Burns JC, Chen SR, Moon HK, Lange C, Randolph AG, Khurana S. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022 05 27; 13(1):2979.
-
El-Shennawy L, Hoffmann AD, Dashzeveg NK, McAndrews KM, Mehl PJ, Cornish D, Yu Z, Tokars VL, Nicolaescu V, Tomatsidou A, Mao C, Felicelli CJ, Tsai CF, Ostiguin C, Jia Y, Li L, Furlong K, Wysocki J, Luo X, Ruivo CF, Batlle D, Hope TJ, Shen Y, Chae YK, Zhang H, LeBleu VS, Shi T, Swaminathan S, Luo Y, Missiakas D, Randall GC, Demonbreun AR, Ison MG, Kalluri R, Fang D, Liu H. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat Commun. 2022 01 20; 13(1):405.
-
Demonbreun AR, Velez MP, Saber R, Ryan DT, Sancilio A, McDade TW, McNally EM. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. Neuromuscul Disord. 2022 01; 32(1):33-35.
-
Changrob S, Fu Y, Guthmiller JJ, Halfmann PJ, Li L, Stamper CT, Dugan HL, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson SA, Utset HA, Graves HM, Amanat F, Sather DN, Krammer F, Kawaoka Y, Wilson PC. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. mBio. 2021 12 21; 12(6):e0297521.
-
Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Pesce L, Saber R, Vaught LA, Reiser NL, Hsieh RR, D'Aquila RT, Mustanski B, McDade TW, McNally EM. COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. J Infect Dis. 2021 09 01; 224(5):793-797.
-
Sancilio AE, D'Aquila RT, McNally EM, Velez MP, Ison MG, Demonbreun AR, McDade TW. A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples. Sci Rep. 2021 07 28; 11(1):15321.
-
Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021 06 08; 54(6):1290-1303.e7.
-
Slezak T, Kossiakoff AA. Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection. J Mol Biol. 2021 05 14; 433(10):166956.
-
Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, Li H, Brasher NA, Christ D, Rouet R, Burnet D, Grubor-Bauk B, Rawlinson W, Turville S, Aggarwal A, Stella AO, Fichter C, Brilot F, Mina M, Post JJ, Hudson B, Gilroy N, Dwyer D, Sasson SC, Tea F, Pilli D, Kelleher A, Tedla N, Lloyd AR, Martinello M, Bull RA. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Rep Med. 2021 04 20; 2(4):100228.
-
Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity. J Virol. 2020 11 09; 94(23).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|